Last reviewed · How we verify

Catapresan TTS 2

Heart Care Foundation · FDA-approved active Small molecule

Clonidine reduces blood pressure by stimulating alpha-2 adrenergic receptors in the brain, decreasing sympathetic nervous system activity.

Clonidine reduces blood pressure by stimulating alpha-2 adrenergic receptors in the brain, decreasing sympathetic nervous system activity. Used for Hypertension.

At a glance

Generic nameCatapresan TTS 2
SponsorHeart Care Foundation
Drug classCentral alpha-2 adrenergic agonist
TargetAlpha-2 adrenergic receptor
ModalitySmall molecule
Therapeutic areaCardiovascular
PhaseFDA-approved

Mechanism of action

Clonidine is a central-acting alpha-2 adrenergic agonist that binds to presynaptic alpha-2 receptors in the brainstem, reducing the release of norepinephrine and decreasing overall sympathetic outflow. This leads to reduced peripheral vascular resistance and lower heart rate, resulting in decreased blood pressure. The transdermal formulation (TTS) provides sustained drug delivery over several days.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: